4.4 Article Proceedings Paper

Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET

期刊

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
卷 18, 期 4, 页码 655-661

出版社

MARY ANN LIEBERT INC PUBL
DOI: 10.1089/108497803322287745

关键词

zirconium-89; iodine-124; positron emission tomography; monoclonal antibodies; xenograft-bearing nude mice

向作者/读者索取更多资源

Antibody-PET imaging might be of value for the selection of radioimmunotherapy (RIT) candidates to confirm tumor targeting and to estimate radiation doses to tumor and normal tissues. One of the requirements to be set for such a scouting procedure is that the biodistributions of the diagnostic and therapeutic radioimmunoconjugates should be similar. In the present study we evaluated the potential of the positron emitters zirconium-89 (Zr-89) and iodine-124 (I-124) for this approach, as these radionuclides have a relatively long half-life that matches with the kinetics of MAbs in vivo (t(1/2) 3.27 and 4.18 days, respectively). After radiolabeling of the head and neck squamous cell carcinoma (HNSCC)-selective chimeric antibody (cMAb) U36, the biodistribution of two diagnostic (cMAb U36-N-sucDf-Zr-89 and cMAb U36-I-124) and three therapeutic radioimmunoconjugates (cMAb U36-p-SCN-Bz-DOTA-Y-88-with Y-88 being substitute for Y-90, cMAb U36-I-131, and cMAb U36-MAG3-Re-186) was assessed in mice with HNSCC-xenografts, at 24, 48, and 72 hours after injection. Two patterns of biodistribution were observed, one pattern matching for Zr-89- and Y-88-labeled cMAb U36 and one pattern matching for I-124-, I-131-, and Re-186-cMAb U36. The most remarkable differences between both patterns were observed for uptake in tumor and liver. Tumor uptake levels were 23.2 +/- 0.5 and 24.1 +/- 0.7%ID/g for the Zr-89- and Y-88-cMAb U36 and 16.0 +/- 0.8, 15.7 +/- 0.79 and 17.1 +/- 1.6%ID/g for I-124-, I-131-, and Re-186-cMAb U36-conjugates, respectively, at 72 hours after injection. For liver these values were 6.9 +/- 0.8 (Zr-89), 6.2 +/- 0.8 (Y-88), 1.7 +/- 0.1 (I-124), 1.6 +/- 0.1 (I-131), and 2.3 +/- 0.1 (Re-186), respectively. These preliminary data justify the further development of antibody-PET with Zr-89-labeled MAbs for scouting of therapeutic doses of Y-90-labeled MAbs. In such approach I-124-labeled MAbs are most suitable for scouting of I-131- and Re-186-labeled MAbs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据